These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 10369954)
1. Economic evaluation studies in nuclear medicine: the need for standardization. Dietlein M; Knapp WH; Lauterbach KW; Schicha H Eur J Nucl Med; 1999 Jun; 26(6):663-80. PubMed ID: 10369954 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427 [TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
4. Clinical and economic outcomes assessment in nuclear cardiology. Shaw LJ; Miller DD; Berman DS; Hachamovitch R Q J Nucl Med; 2000 Jun; 44(2):138-52. PubMed ID: 10967624 [TBL] [Abstract][Full Text] [Related]
5. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy. Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004 [TBL] [Abstract][Full Text] [Related]
6. Economic evaluation studies in nuclear medicine: a methodological review of the literature. Gambhir SS; Schwimmer J Q J Nucl Med; 2000 Jun; 44(2):121-37. PubMed ID: 10967623 [TBL] [Abstract][Full Text] [Related]
7. [Quality criteria for cost-benefit analysis in oncologic nuclear medicine and state of its realization]. Dietlein M; Scheidhauer K; Lauterbach KW; Schicha H Z Arztl Fortbild Qualitatssich; 1999 Jan; 93(1):49-55. PubMed ID: 10198979 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995 [TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness of radiopharmaceuticals in the hospital]. Fotopoulos A Hell J Nucl Med; 2005; 8(1):29. PubMed ID: 15886749 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Garber AM; Solomon NA Ann Intern Med; 1999 May; 130(9):719-28. PubMed ID: 10357690 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H Eur J Nucl Med; 2000 Oct; 27(10):1441-56. PubMed ID: 11083532 [TBL] [Abstract][Full Text] [Related]
12. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Klose T; Leidl R; Buchmann I; Brambs HJ; Reske SN Eur J Nucl Med; 2000 Oct; 27(10):1457-64. PubMed ID: 11083533 [TBL] [Abstract][Full Text] [Related]
13. Virtual chromoendoscopy for the real-time assessment of colorectal polyps in vivo: a systematic review and economic evaluation. Picot J; Rose M; Cooper K; Pickett K; Lord J; Harris P; Whyte S; Böhning D; Shepherd J Health Technol Assess; 2017 Dec; 21(79):1-308. PubMed ID: 29271339 [TBL] [Abstract][Full Text] [Related]
14. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Griebsch I; Coast J; Brown J Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026 [TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018 [TBL] [Abstract][Full Text] [Related]
16. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186 [TBL] [Abstract][Full Text] [Related]